$VANI Cashflow Statement | Understand Stock

$VANI

$1.14 +$0.01 (0.88%) Close

$VANI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment
Stock-based compensation
PPP loan forgiveness
Reclassification of foreign currency translation adjustments
Equipment write-off and loss on equipment disposal
Gain on bargain purchase
Non-cash lease expense
Changes in operating assets and liabilities:
R&D tax credit incentive receivable
Prepaid expenses and other assets
Accounts payable
Accrued compensation expenses
Accrued clinical trial and grant expenses
Accrued expenses
Net cash used in operating activities

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock and exercise of options and warrants
Debt financing (repayment)
Proceeds from exercise of options, warrants and employee stock purchase plan options
Cash acquired in merger for stock consideration
Proceeds from SAFE note
Proceeds from sale of common stock and exercise of options
Proceeds from issuance of common stock and warrants in connection with Securities Purchase Agreement, net of issuance costs
Proceeds from issuance of common stock in connection with the Sales Agreement, net of issuance costs
Proceeds from issuance of common stock in connection with director private securities purchase agreement, net of issuance costs
Proceeds from exercise of common stock options
Proceeds from issuance of common stock in connection with 2025 Private Sales Transaction, net of issuance costs
Proceeds from issuance of common stock in connection with 2025 Registered Direct Offering, net of issuance costs
Proceeds from issuance of common stock in connection with 2025 Private Placement, net of issuance costs
Gross proceeds from insurance premium loan
Principal payment for insurance premium loan
Net cash provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
Net (decrease) in cash, cash equivalents and restricted cash
Balance at beginning of year
Balance at end of year
Cash, cash equivalents and restricted cash balance at beginning of year
Cash, cash equivalents and restricted cash balance at end of year
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Establishment of operating right-of-use assets through operating lease obligations
Cancellation of SAFE indebtedness in merger
Net liabilities acquired in merger for stock consideration
Receivables for cash in-transit on exercise of common stock under equity incentive plan
Purchase of property and equipment in accrued expenses

Comments